AAREY DRUGS & PHARMACEUTICALS LTD.

Aarey Drugs & Pharmaceuticals Ltd has issued a disclosure under SEBI regulations regarding its 36th Annual General Meeting (AGM) scheduled for September 30, 2026. The AGM will be conducted via Video Conferencing. The company has also provided a web link for shareholders who have not registered their email addresses, allowing them to access the Integrated Annual Report for the Financial Year 2025-26 on the company's website. Shareholders are encouraged to update their contact details for future communications and to support green initiatives.

Aarey Drugs & Pharmaceuticals Ltd has issued a notice for its 36th Annual General Meeting (AGM) scheduled for September 30, 2026, at 3:00 PM. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company is circulating its Integrated Annual Report for the financial year 2025-26 along with the AGM notice to shareholders electronically. The report and notice are also available on the company's website. Key agenda items include the adoption of the audited financial statements for FY 2025-26, and the re-appointment of Mrs. Bina Ghatalia as a Director retiring by rotation. Approval of related party transactions is also on the agenda as special business.

Aarey Drugs & Pharmaceuticals Ltd has announced its 36th Annual General Meeting (AGM) for the financial year 2025-26. The AGM is scheduled to be held on Wednesday, September 30, 2026, at 03:00 PM through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company will also circulate its Integrated Annual Report for FY 2025-26 to shareholders electronically. Key agenda items include the adoption of the audited financial statements for the year ended March 31, 2026, and the re-appointment of Mrs. Bina Ghatalia as a Director. The notice also details the e-voting period, which starts on September 27, 2026, at 09:00 AM and ends on September 29, 2026, at 05:00 PM, with a cut-off date of September 23, 2026, for e-voting eligibility.

Aarey Drugs & Pharmaceuticals Ltd held a Board of Directors meeting on September 5, 2026. The board approved the draft Board Report, Annual Report, and the notice for the 36th Annual General Meeting (AGM) for the financial year ending March 31, 2026. The 36th AGM is scheduled for September 30, 2026, to be conducted via Video Conferencing/Other Audio Visual Means. The board also approved the book closure for the register of members and transfer books, setting a cut-off date for e-voting. Additionally, Mr. Virendra G. Bhatt was appointed as the scrutinizer for the e-voting process at the AGM.

Aarey Drugs & Pharmaceuticals Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results, along with the Limited Review Report and MD/CFO certification. A statement on deviation or variation in the utilization of funds raised through convertible warrants (preferential issue) was also considered and approved. The company confirmed its single business segment. The trading window will reopen 48 hours after the announcement of these results.

Aarey Drugs & Pharmaceuticals Ltd announced the outcome of its board meeting held on August 14, 2026. The board considered and approved the Unaudited Financial Results for the first quarter ended June 30, 2026, on a standalone basis. The approval also included the Limited Review Report and MD/CFO certification. Additionally, the board reviewed the Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue). The trading window will reopen 48 hours after the announcement of these results.

Aarey Drugs & Pharmaceuticals Ltd has announced that its Board of Directors meeting is scheduled for August 14, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the limited review report. Additionally, the board will discuss any other matters with the Chairman's consent. In line with SEBI regulations, the company has closed its trading window from July 1, 2026, which will remain shut for 48 hours post the announcement of the financial results.

Aarey Drugs & Pharmaceuticals Ltd announced the allotment of 2,520,000 Equity Shares following the conversion of fully convertible warrants. The conversion was based on receipt of Rs. 47.85 per warrant, representing 75% of the issue price of Rs. 63.80. This allotment, aggregating to Rs. 12,05,82,000/-, was made to both promoter and non-promoter categories. The company's issued and paid-up capital has increased accordingly. Out of 5,000,000 warrants initially issued, 2,520,000 have been converted, leaving 2,480,000 warrants outstanding.

Aarey Drugs & Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. Designated persons and their immediate relatives are prohibited from trading in the company's shares during this period to prevent insider trading.

Aarey Drugs & Pharmaceuticals Ltd's board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026. The company reported revenue from operations of ₹473.94 million and a profit of ₹3.96 million for the year ended March 31, 2026. The board meeting, which commenced at 5:00 P.M. and concluded at 7:20 P.M., also approved a statement of deviation or variation in utilization of funds raised through convertible warrants.